%PDF-1.4
%
162 0 obj
<>>>
endobj
163 0 obj
<>/Font<>>>/Fields[]>>
endobj
159 0 obj
<>
endobj
156 0 obj
<>stream
Adobe PDF Library 15.0
False
2019-03-18T09:51:22+08:00
2019-03-20T11:33:08-07:00
2019-03-20T11:33:08-07:00
Adobe InDesign CC 2017 (Windows)
uuid:29587791-1dd2-11b2-0a00-b000185de8ff
xmp.did:f4fd3488-9b3f-9d45-a5a3-8a4b2d55f952
xmp.id:9cf23b7a-383f-ae45-bfda-f2278ad189c6
proof:pdf
xmp.iid:13d5424a-7438-d448-bd34-5d85d3e6dde9
xmp.did:3c1a44db-b4cf-7e40-805f-12478d22c8a0
xmp.did:f4fd3488-9b3f-9d45-a5a3-8a4b2d55f952
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2019-03-18T09:51:22+08:00
application/pdf
Science Journals — AAAS
endstream
endobj
149 0 obj
<>
endobj
157 0 obj
<>
endobj
13 0 obj
<>
endobj
62 0 obj
<>
endobj
43 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/Rotate 0/Thumb 44 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
64 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/Properties<>/XObject<>>>/Rotate 0/Thumb 65 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
88 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 89 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
91 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 92 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
94 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 95 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
100 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 101 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
103 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 104 0 R/TrimBox[0 0 594 756]/Type/Page>>
endobj
208 0 obj
<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/Type/Page>>
endobj
229 0 obj
[234 0 R 235 0 R 236 0 R 237 0 R 238 0 R 239 0 R 240 0 R 241 0 R]
endobj
230 0 obj
<>stream
q
304.25 0 0 21.75 84 662.25 cm
/Im0 Do
Q
BT
/T1_0 1 Tf
10 0 0 10 84 611.99997 Tm
(cancer)Tj
0 1 TD
(Delta-like protein 3 expression and therapeutic targeting in neuroendocr\
ine prostate)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 84 574.99991 Tm
(Juan Miguel Mosquera, Laura Saunders and Himisha Beltran)Tj
T*
(Andrea Sboner, Yuzhuo Wang, Ryan Dittamore, David Rickman, David M. Nanu\
s, Scott T. Tagawa, Olivier Elemento,)Tj
0 1.00001 TD
(Megan Kearney, Aram Vosoughi, Luisa Fernandez, Heng Pan, Samaneh Motanag\
h, Judy Hess, Adam J. Donoghue, )Tj
0 1 TD
(Loredana Puca, Katie Gavyert, Verena Sailer, Vincenza Conteduca, Etienne\
Dardenne, Michael Sigouros, Kumiko Isse,)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 84 528.99997 Tm
(DOI: 10.1126/scitranslmed.aav0891)Tj
8.05798 1 Td
(, eaav0891.)Tj
/T1_0 1 Tf
-1.112 0 Td
(11)Tj
/T1_2 1 Tf
-6.94598 0 Td
(Sci Transl Med )Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 104 440.99979 Tm
(as well as a human patient.)Tj
T*
(aggressive clinical features. They then demonstrated the effectiveness o\
f targeting DLL3 in multiple mouse models)Tj
0 1.00001 TD
(neuroendocrine prostate cancers, but not in localized tumors or normal p\
rostate, and showed its association with )Tj
0 1 TD
(cell lung cancer, another aggressive neuroendocrine tumor. The authors c\
onfirmed the presence of DLL3 in most)Tj
0 1.00001 TD
(antibody-drug conjugate against delta-like protein 3 \(DLL3\), a recentl\
y identified therapeutic being tested in small )Tj
23.17798 1 Td
(. demonstrate the feasibility of targeting it with an)Tj
/T1_2 1 Tf
-1.89 0 Td
(et al)Tj
/T1_1 1 Tf
-21.28798 0 Td
(disease and drive therapeutic resistance. Puca )Tj
3.125 1 Td
(Neuroendocrine prostate cancer is an aggressive tumor subtype that can a\
rise late in the course of the)Tj
/T1_0 1 Tf
-3.125 1.00001 Td
(Lessons from one tumor help with another)Tj
ET
BT
/T1_0 1 Tf
6 0 0 6 91 395 Tm
(ARTICLE TOOLS)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 199 393 Tm
(http://stm.sciencemag.org/content/11/484/eaav0891)Tj
ET
BT
0 g
/T1_0 1 Tf
6 0 0 6 91 352.99997 Tm
(MATERIALS)Tj
T*
(SUPPLEMENTARY )Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 199 357 Tm
(http://stm.sciencemag.org/content/suppl/2019/03/18/11.484.eaav0891.DC1)Tj
ET
BT
0 g
/T1_0 1 Tf
6 0 0 6 91 310.99997 Tm
(CONTENT)Tj
T*
(RELATED )Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 199 306.99997 Tm
(http://stm.sciencemag.org/content/scitransmed/5/187/187ra71.full)Tj
0 1 TD
(http://stm.sciencemag.org/content/scitransmed/7/302/302ra136.full)Tj
ET
BT
0 g
/T1_0 1 Tf
6 0 0 6 91 275 Tm
(REFERENCES)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 199 264.99997 Tm
(http://stm.sciencemag.org/content/11/484/eaav0891#BIBL)Tj
0 g
T*
(This article cites 44 articles, 17 of which you can access for free)Tj
ET
BT
/T1_0 1 Tf
6 0 0 6 91 239 Tm
(PERMISSIONS)Tj
ET
BT
0 0 1 rg
/T1_1 1 Tf
8 0 0 8 199 237 Tm
(http://www.sciencemag.org/help/reprints-and-permissions)Tj
ET
BT
/T1_1 1 Tf
8 0 0 8 205.38391 128 Tm
(Terms of Service)Tj
0 g
-15.17299 0 Td
(Use of this article is subject to the )Tj
ET
84 114 m
510 114 l
0 0 m
S
BT
ET
BT
/T1_1 1 Tf
8 0 0 8 211.59985 77.99991 Tm
( is a registered trademark of AAAS.)Tj
/T1_2 1 Tf
-13.83798 0 Td
(Science Translational Medicine)Tj
/T1_1 1 Tf
-2.112 0 Td
(title )Tj
T*
(licensee American Association for the Advancement of Science. No claim t\
o original U.S. Government Works. The)Tj
0 1.00001 TD
(Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 \251 The Au\
thors, some rights reserved; exclusive )Tj
14.11598 1 Td
(\(ISSN 1946-6242\) is published by the American Association for the Adva\
ncement of)Tj
/T1_2 1 Tf
-14.11598 0 Td
(Science Translational Medicine )Tj
ET
BT
/T1_1 1 Tf
0 -8 8 0 578 349.33209 Tm
( by guest on March 20, 2019)Tj
0 0 1 rg
-11.72697 0 Td
(http://stm.sciencemag.org/)Tj
0 g
-8.11399 0 Td
(Downloaded from )Tj
ET
endstream
endobj
233 0 obj
<>/Filter/FlateDecode/Height 87/Length 66928/Name/X/Subtype/Image/Type/XObject/Width 1217>>stream
HT{gf
(Kbc`$H1)1cZ=&Vi1IGi4ԪTL@9DARPy.(1硫3̽f XU]ksM&D3㘀L}E